Subretinal fluid volatility may play a key role in predicting visual acuity outcomes of neovascular age-related macular degeneration, according to research presented at the virtual American Academy of Ophthalmology annual meeting.
Justis P. Ehlers, MD, of Cleveland Clinic, and colleagues enrolled 90 treatment naive patients comparing 2 mg of Eylea (aflibercept, Regeneron) with 6 mg Beovu (brolucizumab, Novartis) over 56 weeks.
“Trained expert readers validated the accuracy of the segmentation, each macular scan from baseline to week 56 was automatically segmented for each of these key
Uncategorized